

# **Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy**

ICRU Report 83

ISBN: 978-1-5108-8924-8

**Printed from e-media with permission by:**

Curran Associates, Inc.  
57 Morehouse Lane  
Red Hook, NY 12571



**Some format issues inherent in the e-media version may also appear in this print version.**

Published by Sage Publications USA

Copyright© (2010) by International Commission on Radiation Units and Measurements (ICRU)  
All rights reserved.

ISBN (Print) 978-1-5108-8924-8

Printed by Curran Associates, Inc. (2019)

For permission requests, please contact [sagepub.com/journals-permissions](http://sagepub.com/journals-permissions)

**Additional copies of this publication are available from:**

Curran Associates, Inc.  
57 Morehouse Lane  
Red Hook, NY 12571 USA  
Phone: 845-758-0400  
Fax: 845-758-2633  
Email: [curran@proceedings.com](mailto:curran@proceedings.com)  
Web: [www.proceedings.com](http://www.proceedings.com)

# Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT)

## Contents

<b>Preface</b> .....	1
<b>Abstract</b> .....	3
<b>Executive Summary</b> .....	5
<b>1 Introduction</b> .....	7
<b>1.1 Overview of Intensity-Modulated Radiation Therapy (IMRT)</b> .....	7
<b>1.1.1 From Three-Dimensional Conformal (3D-CRT) to Intensity-Modulated Radiation Therapy</b> .....	8
<b>1.1.2 Delivery of IMRT</b> .....	8
<b>1.1.3 Clinical Experience with IMRT</b> .....	9
<b>1.2 Issues Common to Both 3D-CRT and IMRT</b> .....	11
<b>1.2.1 Imaging and 4D Adaptive Treatment</b> .....	11
<b>1.2.2 Margins and Uncertainties</b> .....	13
<b>1.2.3 Radiation-Induced Secondary Cancers</b> .....	14
<b>1.3 Aim of the Present Report and Relation to Existing ICRU Reports</b> .....	15
<b>2 Optimized Treatment Planning For IMRT</b> .....	17
<b>2.1 Introduction</b> .....	17
<b>2.2 Comparison of 3D-Conformal and IMRT Treatment Planning</b> .....	17
<b>2.3 Overview of the Optimization Process</b> .....	18
<b>2.4 Examples of an Objective Function and the Iterative Optimization Process</b> .....	20
<b>2.5 Iterative Search for an Improved Absorbed-Dose Distribution</b> .....	22
<b>2.6 Beamlet Optimization and Aperture-Based Optimization</b> .....	24
<b>2.7 Optimization Incorporating Biological Information</b> .....	25
<b>3 Special Considerations Regarding Absorbed-Dose and Dose–Volume Prescribing and Reporting in IMRT</b> .....	27
<b>3.1 The ICRU Reference Point and ICRU Reference Dose</b> .....	27
<b>3.1.1 Conventional Reporting of Point Absorbed Doses</b> .....	27
<b>3.1.2 Dose–Volume Calculations</b> .....	28
<b>3.2 Level 2 Prescribing and Reporting For IMRT</b> .....	28
<b>3.3 Impact of Modern Treatment-Planning Techniques</b> .....	30
<b>3.4 Dose–Volume Reporting Specific to the OAR and PRV</b> .....	33
<b>3.5 Reporting of Treatment Fields Delivered per Fraction</b> .....	34
<b>3.6 Reporting of Software Versions for Treatment Planning and Delivery</b> .....	34
<b>3.7 Level 3 Reporting: Reporting Developmental Techniques and Concepts</b> .....	34

*PRESCRIBING, RECORDING, AND REPORTING PHOTON-BEAM IMRT*

3.7.1	Dose Homogeneity and Dose Conformity .....	34
3.7.2	Clinical and Biological Evaluation Metrics .....	36
3.7.3	Equivalent Uniform Dose .....	38
3.8	Reporting of Confidence Intervals .....	38
4	Definition of Volumes .....	41
4.1	Introduction .....	41
4.2	Gross Tumor Volume (GTV) .....	42
4.3	Clinical Target Volume (CTV) .....	44
4.4	Internal Target Volume (ITV) .....	46
4.5	Planning Target Volume (PTV) .....	46
4.6	Organ at Risk (OAR) .....	49
4.7	Planning Organ at Risk Volume (PRV) .....	52
4.8	Treated Volume (TV) .....	53
4.9	Remaining Volume at Risk (RVR) .....	53
5	Planning Aims, Prescription, and Technical Data .....	55
5.1	Introduction .....	55
5.2	Planning Aims .....	55
5.3	Special Situations Illustrating the Use of Planning Aims .....	56
5.3.1	Dose Planning in the Buildup Region and in a PTV Extending Outside the Body Contour .....	56
5.3.2	Overlapping Volumes and Conflicting Planning Aims .....	57
5.3.3	Unexpected High Dose to the RVR .....	58
5.4	Treatment Plan .....	58
5.4.1	Prescription .....	58
5.4.2	Technical Data .....	58
Appendix A:	Physical Aspects of IMRT .....	61
A1	Absorbed-Dose Computation .....	61
A.1.1	Photon Interactions and the Energy-Deposition Processes .....	61
A.1.2	Modeling the Beam .....	63
A.1.3	Dose-Calculation Algorithms .....	63
A.1.4	Calculation of Absorbed Dose per Monitor Unit .....	66
A.2	Commissioning and Quality Assurance .....	68
A.2.1	Commissioning of Treatment-Planning Systems .....	68
A.2.2	Quality Assurance of IMRT Delivery Systems .....	69
A.2.2.1	Conventional-MLC Delivery Systems .....	69
A.2.2.2	Binary MLC Delivery Systems .....	73
A.2.3	Patient-Specific Quality Assurance .....	75
A.2.3.1	Measurements of Intensity from Individual Beams .....	76
A.2.3.2	Measurements of Absorbed Dose in Phantoms .....	76
A.2.3.3	Independent Absorbed-Dose Calculations .....	77
A.2.3.4	<i>In-Vivo</i> Dosimetry .....	78
A.2.3.5	Recommendations for Accuracy of Absorbed-Dose Delivery .....	79
Appendix B:	Clinical Examples .....	83
B.1	Case Number B1. Squamous-Cell Carcinoma of the Supra-Glottic Larynx .....	83
B.1.1	Clinical Situation .....	83
B.1.2	Treatment Intent .....	83
B.1.3	Patient Positioning and Image Acquisition .....	83
B.1.4	Target Volumes .....	84
B.1.4.1	Gross Tumor Volume .....	84

*TABLE OF CONTENTS*

B.1.4.2	Clinical Target Volume .....	84
B.1.4.3	Planning Target Volume .....	84
B.1.4.4	Organs at Risk and Planning Organ-at-Risk Volume.....	84
B.1.5	Planning Aim .....	85
B.1.6	Treatment-Planning System and Treatment Unit.....	85
B.1.7	Prescription .....	85
B.1.8	Quality Assurance .....	86
B.1.9	Dose Reporting .....	87
B.2	Case Number B2. Squamous-Cell Carcinoma of the Lung .....	87
B.2.1	Clinical Situation .....	87
B.2.2	Treatment Intent .....	87
B.2.3	Patient Positioning and Image Acquisition.....	87
B.2.4	Target Volumes .....	88
B.2.4.1	Gross Tumor Volume .....	88
B.2.4.2	Clinical Target Volume .....	88
B.2.4.3	Planning Target Volume .....	88
B.2.4.4	Organs at Risk and Planning Organ-at-Risk Volume.....	88
B.2.5	Planning Aim .....	89
B.2.6	Treatment-Planning System and Treatment Unit.....	89
B.2.7	Prescription .....	90
B.2.8	Quality Assurance .....	90
B.2.9	Dose Reporting and Plan Evaluation.....	91
B.3	Case Number B3. Adenocarcinoma of the Prostate.....	91
B.3.1	Clinical Situation .....	91
B.3.2	Treatment Intent .....	91
B.3.3	Patient Positioning and Image Acquisition.....	91
B.3.4	Target Volumes .....	91
B.3.4.1	GrossTumor Volume.....	91
B.3.4.2	Clinical Target Volume .....	91
B.3.4.3	Planning Target Volume .....	91
B.3.4.4	Organs at Risk and Planning Organ-at-Risk Volume.....	91
B.3.5	Planning Aim .....	91
B.3.6	Treatment-Planning System and Treatment Unit.....	91
B.3.7	Prescription .....	92
B.3.8	Quality Assurance .....	92
B.3.9	Dose Reporting .....	92
References.....		93